Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations- a randomized study evaluated in a tumour-free porcine model.

IF 2.3 4区 医学 Q3 ONCOLOGY Cancer Chemotherapy and Pharmacology Pub Date : 2025-03-24 DOI:10.1007/s00280-025-04768-7
Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Christina Harlev, Elisabeth Krogsgaard Petersen, Hans Christian Rasmussen, Jakob Hansen, Thomas Baad Hansen, Akmal Safwat, Maiken Stilling
{"title":"Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations- a randomized study evaluated in a tumour-free porcine model.","authors":"Andrea René Jørgensen, Mats Bue, Pelle Hanberg, Christina Harlev, Elisabeth Krogsgaard Petersen, Hans Christian Rasmussen, Jakob Hansen, Thomas Baad Hansen, Akmal Safwat, Maiken Stilling","doi":"10.1007/s00280-025-04768-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate plasma and bone- and soft-tissue concentrations of doxorubicin following two administrations of either bolus or continuous infusion administered at a three-week interval. The achievement of adequate concentration at target sites is believed to be positively correlated to effect, and it has been suggested that concentrations are affected by the number of administrations.</p><p><strong>Methods: </strong>Eighteen female pigs were included in the study and randomized into two groups of nine receiving either a bolus or continuous infusion. The animals received a dosage of 2 mg/kg on day 1 and on day 22. From day 1 to 10, doxorubicin concentrations, as well as kidney and liver function, were monitored with plasma samples (total concentrations). On day 22, doxorubicin was measured in plasma samples (total concentration) and microdialysates (unbound concentrations) from subcutaneous tissue, muscle, synovial fluid of the knee joint, cancellous bone, and intravenously.</p><p><strong>Results: </strong>On day 22, the pharmacokinetic profiles were comparable between the two groups except for plasma AUC<sub>0 - 12 h</sub>, which was higher after continuous infusion, and intravenous C<sub>max</sub>, which was higher after bolus infusion. Bone- and soft tissue concentrations were below 0.10 µg/mL. Except for mean plasma (total) concentration at the 6 h timepoint on day 1 and 22 in the continuous group, which was higher after the first administration (p = 0.037), no differences in plasma concentrations were found between the two administrations.</p><p><strong>Conclusion: </strong>Low mean tissue doxorubicin concentrations and similar pharmacokinetic profiles were found between the bolus and continuous infusion groups. Thus, similar anti-neoplastic efficacy is to be expected with both administration types.</p>","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":"95 1","pages":"47"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930866/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Chemotherapy and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00280-025-04768-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The aim of this study was to evaluate plasma and bone- and soft-tissue concentrations of doxorubicin following two administrations of either bolus or continuous infusion administered at a three-week interval. The achievement of adequate concentration at target sites is believed to be positively correlated to effect, and it has been suggested that concentrations are affected by the number of administrations.

Methods: Eighteen female pigs were included in the study and randomized into two groups of nine receiving either a bolus or continuous infusion. The animals received a dosage of 2 mg/kg on day 1 and on day 22. From day 1 to 10, doxorubicin concentrations, as well as kidney and liver function, were monitored with plasma samples (total concentrations). On day 22, doxorubicin was measured in plasma samples (total concentration) and microdialysates (unbound concentrations) from subcutaneous tissue, muscle, synovial fluid of the knee joint, cancellous bone, and intravenously.

Results: On day 22, the pharmacokinetic profiles were comparable between the two groups except for plasma AUC0 - 12 h, which was higher after continuous infusion, and intravenous Cmax, which was higher after bolus infusion. Bone- and soft tissue concentrations were below 0.10 µg/mL. Except for mean plasma (total) concentration at the 6 h timepoint on day 1 and 22 in the continuous group, which was higher after the first administration (p = 0.037), no differences in plasma concentrations were found between the two administrations.

Conclusion: Low mean tissue doxorubicin concentrations and similar pharmacokinetic profiles were found between the bolus and continuous infusion groups. Thus, similar anti-neoplastic efficacy is to be expected with both administration types.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
反复给药和连续给药阿霉素对骨和软组织浓度的影响——一项在无肿瘤猪模型中评估的随机研究。
目的:本研究的目的是评估阿霉素在两次大剂量或连续输注后的血浆、骨和软组织浓度。在目标地点达到适当的浓度被认为与效果呈正相关,并且有人认为浓度受到施用次数的影响。方法:选取18头雌性猪,随机分为两组,每组9头,分别给药和持续给药。第1天和第22天分别给予2 mg/kg的剂量。从第1天到第10天,用血浆样本(总浓度)监测阿霉素浓度以及肾功能和肝功能。第22天,测量血浆样品(总浓度)和皮下组织、肌肉、膝关节滑液、松质骨微透析液(未结合浓度)中的阿霉素,并静脉注射。结果:在第22天,两组药代动力学除了持续输注后血浆AUC0 - 12 h较高,静脉内Cmax较高外,其余均具有可比较性。骨组织和软组织浓度低于0.10µg/mL。除连续用药组第1天和第22天6 h时平均血浆(总)浓度高于第一次给药组(p = 0.037)外,两次给药组间血浆浓度无差异。结论:大剂量组和连续输注组的阿霉素平均组织浓度较低,药代动力学特征相似。因此,两种给药类型的抗肿瘤效果相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
3.30%
发文量
116
审稿时长
2.5 months
期刊介绍: Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field. The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy.
期刊最新文献
Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFV600E/K-mutant metastatic melanoma. Retraction Note: Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats. Effect of high-dose methotrexate infusion duration on 48-hour drug levels and toxicity in children with acute lymphoblastic leukaemia: a quality-of-care study. KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1